PE20010070A1 - COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2 - Google Patents
COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2Info
- Publication number
- PE20010070A1 PE20010070A1 PE2000000399A PE0003992000A PE20010070A1 PE 20010070 A1 PE20010070 A1 PE 20010070A1 PE 2000000399 A PE2000000399 A PE 2000000399A PE 0003992000 A PE0003992000 A PE 0003992000A PE 20010070 A1 PE20010070 A1 PE 20010070A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- optionally substituted
- compounds
- methyl
- pyrimidinone compounds
- Prior art date
Links
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title abstract 3
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 title 1
- 108010024976 Asparaginase Proteins 0.000 title 1
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- -1 N-METHYL-N- (4- (4-CHLOROPHENYL) BENZYL) AMINOCARBONYLMETHYL Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 108010058864 Phospholipases A2 Proteins 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS DE PIRIMIDINONA DE FORMULA I, DONDE: R1 ES ARILO, HETEROARILO OPCIONALMENTE CON ALQUILO C1-C18, OH, HALOGENO, CN, NR6COR7, ENTRE OTROS; R2 ES ARILO, HETEROARILO, OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C18, ENTRE OTROS; R3 ES H, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON OH, OR6, COR6, CARBOXI, COOR6, CONR9R10, NR9R10, ENTRE OTROS; R4 ES ARIL, HETEROARIL OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C18, ALCOXI C1-C18, ENTRE OTROS; R5 ES ARIL, HETEROARIL OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C18, ALCOXI C1-C18, NR6COR7, ENTRE OTROS; R6 Y R7 SON H, ALQUILO C1-C20; R8 ES ALQUILO C1-C4, R9 Y R10 SON H, ALQUILO C1-C12, ENTRE OTROS; n ES 1-4; X ES O, S; Z ES CR13R14; R13 Y R14 SON H, ALQUILO C1-C4 O JUNTO A C FORMAN UN CICLOALQUILO C3-C6. SON COMPUESTOS PREFERIDOS 1-(N-METIL-N-(4-(4-CLOROFENIL)BENCIL)AMINOCARBONILMETIL)-2-(4-FLUOROBENCIL)TIO-5-(1-METIL-PIRAZOL-4-ILMETIL)PIRIMIDIN-4-ONA; 1-(N-METIL-N-(4-(4-TRIFLUOROMETILFENIL)BENCIL)AMINOCARBONILMETIL-2-(4-FLUOROBENCIL)TIO-5-(1-METILPIRAZOL-4-ILMETIL)PIRIMIDIN-4-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS COMPUESTOS DE PIRIMIDINONA SON INHIBIDORES DE LA ENZIMA FOSFOLIPASA A2 ASOCIADA A LAS LIPOPROTEINAS (Lp-LPA2) Y PUEDEN SER UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9910048A GB9910048D0 (en) | 1999-05-01 | 1999-05-01 | Novel compounds |
| GB0002096A GB0002096D0 (en) | 2000-01-28 | 2000-01-28 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010070A1 true PE20010070A1 (es) | 2001-03-10 |
Family
ID=26243514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000399A PE20010070A1 (es) | 1999-05-01 | 2000-04-28 | COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6953803B1 (es) |
| EP (2) | EP1479671B1 (es) |
| JP (1) | JP2002543190A (es) |
| KR (1) | KR20020012200A (es) |
| CN (1) | CN1286822C (es) |
| AR (1) | AR023777A1 (es) |
| AT (2) | ATE283845T1 (es) |
| AU (1) | AU766003B2 (es) |
| BR (1) | BR0010220A (es) |
| CA (1) | CA2371671A1 (es) |
| CO (1) | CO5170521A1 (es) |
| CZ (1) | CZ20013904A3 (es) |
| DE (2) | DE60042286D1 (es) |
| DK (1) | DK1175408T3 (es) |
| ES (1) | ES2233361T3 (es) |
| HK (1) | HK1044757B (es) |
| HU (1) | HUP0201122A3 (es) |
| IL (1) | IL146210A0 (es) |
| MX (1) | MXPA01011186A (es) |
| MY (1) | MY136037A (es) |
| NO (1) | NO20015329L (es) |
| NZ (1) | NZ515137A (es) |
| PE (1) | PE20010070A1 (es) |
| PL (1) | PL351690A1 (es) |
| PT (1) | PT1175408E (es) |
| SI (1) | SI1175408T1 (es) |
| TR (1) | TR200103216T2 (es) |
| UY (1) | UY26132A1 (es) |
| WO (1) | WO2000066567A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20013904A3 (cs) * | 1999-05-01 | 2002-04-17 | Smithkline Beecham Plc | Pyrimidinonové sloučeniny |
| WO2001060805A1 (en) | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| CA2530816A1 (en) * | 2003-07-02 | 2005-01-13 | Bayer Healthcare Ag | Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| EP2290094A1 (en) | 2004-04-16 | 2011-03-02 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| DE102004061006A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Benzylthio-1,2,4-triazin-5(2H)-one |
| DE102004061009A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| CN1954826A (zh) * | 2005-10-26 | 2007-05-02 | 上海生物芯片有限公司 | 银杏叶提取物在降低胆固醇方面的用途 |
| JP5437996B2 (ja) | 2007-05-11 | 2014-03-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 皮膚潰瘍の治療方法 |
| BRPI0721697A2 (pt) | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
| UY33388A (es) | 2010-05-17 | 2011-12-01 | Glaxo Group Ltd | Nuevos procesos para la preparacion de compuestos de pirimidinona |
| CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
| MX2013006342A (es) | 2010-12-06 | 2013-08-26 | Glaxo Group Ltd | Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2). |
| ES2847883T3 (es) | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| WO2013000108A1 (zh) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
| AU2012288865B2 (en) | 2011-07-27 | 2015-10-01 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
| KR20140059203A (ko) | 2011-07-27 | 2014-05-15 | 글락소 그룹 리미티드 | 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도 |
| CN103917529B (zh) * | 2011-11-11 | 2016-08-17 | 辉瑞大药厂 | 2-硫代嘧啶酮类 |
| AU2014209949B2 (en) | 2013-01-25 | 2016-09-08 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors |
| JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物 |
| CA2899124A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| US9552473B2 (en) | 2014-05-14 | 2017-01-24 | Microsoft Technology Licensing, Llc | Claiming data from a virtual whiteboard |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
| CN106008362B (zh) * | 2016-05-24 | 2018-08-10 | 杰达维（上海）医药科技发展有限公司 | 一种嘧啶衍生物的制备方法 |
| JP6545747B2 (ja) * | 2017-05-09 | 2019-07-17 | 山田化学工業株式会社 | 色素化合物 |
| BR112022008786A2 (pt) | 2019-11-09 | 2022-07-26 | Shanghai Simr Biotechnology Co Ltd | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1582527A (en) * | 1975-12-29 | 1981-01-07 | Smith Kline French Lab | Pyrimidone and thiopyrimidone derivatives |
| DE69816471T2 (de) | 1997-11-06 | 2004-05-27 | Smithkline Beecham P.L.C., Brentford | Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen |
| JP2002523402A (ja) * | 1998-08-21 | 2002-07-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療用ピリミジノン |
| CZ20013904A3 (cs) * | 1999-05-01 | 2002-04-17 | Smithkline Beecham Plc | Pyrimidinonové sloučeniny |
-
2000
- 2000-04-25 CZ CZ20013904A patent/CZ20013904A3/cs unknown
- 2000-04-25 AT AT00920741T patent/ATE283845T1/de active
- 2000-04-25 US US10/030,661 patent/US6953803B1/en not_active Expired - Lifetime
- 2000-04-25 WO PCT/EP2000/003727 patent/WO2000066567A1/en not_active Ceased
- 2000-04-25 MX MXPA01011186A patent/MXPA01011186A/es active IP Right Grant
- 2000-04-25 HK HK02104602.0A patent/HK1044757B/en not_active IP Right Cessation
- 2000-04-25 SI SI200030609T patent/SI1175408T1/xx unknown
- 2000-04-25 DE DE60042286T patent/DE60042286D1/de not_active Expired - Fee Related
- 2000-04-25 AU AU41203/00A patent/AU766003B2/en not_active Expired
- 2000-04-25 DE DE60016397T patent/DE60016397T2/de not_active Expired - Lifetime
- 2000-04-25 BR BR0010220-2A patent/BR0010220A/pt not_active IP Right Cessation
- 2000-04-25 PL PL00351690A patent/PL351690A1/xx not_active Application Discontinuation
- 2000-04-25 JP JP2000615598A patent/JP2002543190A/ja active Pending
- 2000-04-25 ES ES00920741T patent/ES2233361T3/es not_active Expired - Lifetime
- 2000-04-25 KR KR1020017013976A patent/KR20020012200A/ko not_active Ceased
- 2000-04-25 PT PT00920741T patent/PT1175408E/pt unknown
- 2000-04-25 CN CNB008094918A patent/CN1286822C/zh not_active Expired - Lifetime
- 2000-04-25 NZ NZ515137A patent/NZ515137A/en unknown
- 2000-04-25 HU HU0201122A patent/HUP0201122A3/hu unknown
- 2000-04-25 DK DK00920741T patent/DK1175408T3/da active
- 2000-04-25 TR TR2001/03216T patent/TR200103216T2/xx unknown
- 2000-04-25 IL IL14621000A patent/IL146210A0/xx unknown
- 2000-04-25 EP EP04077397A patent/EP1479671B1/en not_active Expired - Lifetime
- 2000-04-25 EP EP00920741A patent/EP1175408B1/en not_active Expired - Lifetime
- 2000-04-25 AT AT04077397T patent/ATE432265T1/de not_active IP Right Cessation
- 2000-04-25 CA CA002371671A patent/CA2371671A1/en not_active Abandoned
- 2000-04-27 AR ARP000102001A patent/AR023777A1/es not_active Application Discontinuation
- 2000-04-28 CO CO00030779A patent/CO5170521A1/es not_active Application Discontinuation
- 2000-04-28 PE PE2000000399A patent/PE20010070A1/es not_active Application Discontinuation
- 2000-04-28 UY UY26132A patent/UY26132A1/es not_active Application Discontinuation
- 2000-04-28 MY MYPI20001870A patent/MY136037A/en unknown
-
2001
- 2001-10-31 NO NO20015329A patent/NO20015329L/no not_active Application Discontinuation
-
2004
- 2004-02-11 US US10/776,876 patent/US7115616B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010070A1 (es) | COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2 | |
| PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
| PE20040168A1 (es) | Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas | |
| PE20040590A1 (es) | Composiciones de pirrolotriazina anilina como inhibidores de cinasa | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20020756A1 (es) | Imidazotriazinonas sustituidas como inhibidores de la fosfodiesterasa pde 2 | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| AR106755A2 (es) | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos | |
| PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| PE20030129A1 (es) | Imidazotriazinas | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| UY27370A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células y métodos para su utilización | |
| NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
| PE20050896A1 (es) | Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos | |
| EA199900693A1 (ru) | Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов | |
| PE20050077A1 (es) | Derivados de 4-pirrolidino-fenil-bencil-eter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |